Of the other four participants who had hyperkalemia events that were not confirmed with a subsequent lab draw, three were on either an angiotensin converting enzyme inhibitor or angiotensin receptor blocker, and one was on tacrolimus. This evidence concerns the gene ACE and Hyperkalemia.